REVIEW Trihexyphenidyl is a selective M1 muscarinic acetylcholine receptor antagonist. It is able to discriminate between the M1 (cortical or neuronal) and the peripheral muscarinic subtypes (cardiac and glandular). Trihexyphenidyl partially blocks cholinergic activity in the CNS, which is responsible for the symptoms of Parkinson's disease. It is also thought to increase the availability of dopamine, a brain chemical that is critical in the initiation and smooth control of voluntary muscle movement.
REFERENCES
[1]
Giachetti, A.; Giraldo, E.; Ladinsky, H.; Montagna, E. (1986). Binding and functional profiles of the selective M1 muscarinic receptor antagonists trihexyphenidyl and dicyclomine. British Journal of Pharmacology 89 (1): 83-90. PMC 1917044. PMID 2432979.
[2]
Berke, J. D.; Hyman, S. E. (2000). Addiction, dopamine, and the molecular mechanisms of memory. Neuron 25 (3): 515-532. doi:10.1016/S0896-6273(00)81056-9. PMID 10774721.
[3]
Sanger, T. D.; Bastian, A.; Brunstrom, J.; Damiano, D.; Delgado, M.; Dure, L.; Gaebler-Spira, D.; Hoon, A. et al. (2007). Prospective Open-Label Clinical Trial of Trihexyphenidyl in Children with Secondary Dystonia due to Cerebral Palsy. Journal of Child Neurology 22 (5): 530-537. doi:10.1177/0883073807302601. PMID 17690057.
These chemical products are for research and development use only. They are not for diagnostic, therapeutic, cosmetic, or human and animal uses. They are not sold to individuals. Additional restrictions may apply.
New customers undergo an internal onboarding process. As part of this process, new customers may be asked for more information.
Add to Favorites 
Delete from Favorites 
